Comparative Pharmacology
Head-to-head clinical analysis: ALOXI versus GRANISETRON HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOXI versus GRANISETRON HYDROCHLORIDE.
ALOXI vs GRANISETRON HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, preventing nausea and vomiting.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, inhibiting emetic reflex.
0.25 mg intravenously over 30 seconds, administered 30 minutes before chemotherapy on day 1 of each cycle; not to be repeated within 7 days.
2 mg orally once daily or 1 mg intravenously twice daily; alternatively 10 mcg/kg intravenously 30 minutes before chemotherapy for prevention of nausea and vomiting.
None Documented
None Documented
Clinical Note
moderateRaloxifene + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Fluconazole
Terminal elimination half-life is approximately 40 hours (range 33–45 hours) in adults, allowing once-daily dosing for prevention of chemotherapy-induced nausea and vomiting.
Terminal elimination half-life: 7–9 hours (range 4–14 h) in most patients; prolonged in severe hepatic impairment (up to 12–15 h). Half-life is dose-independent.
Renal (approximately 50% unchanged drug), biliary/fecal (approximately 35% as metabolites). Total clearance is 160 ± 38 mL/min.
Renal: ~12% unchanged; fecal: ~34% (as metabolites); biliary: significant contribution; total clearance is 0.38–0.51 L/h/kg.
Category C
Category A/B
5-HT3 Antagonist
5-HT3 Antagonist
"The metabolism of Fluconazole can be decreased when combined with Raloxifene."